{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3A0.9%25+sodium+chloride&page=41",
    "query": {
      "intervention": "Placebo:0.9% sodium chloride",
      "page": 41
    },
    "page_size": 10
  },
  "pagination": {
    "page": 41,
    "page_size": 10,
    "total_count": 1586,
    "total_pages": 159,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3A0.9%25+sodium+chloride&page=42&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3A0.9%25+sodium+chloride&page=40&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T18:29:10.481Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05953480",
      "title": "A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Ischemic Stroke"
      ],
      "interventions": [
        {
          "name": "Redasemtide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Shionogi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 680,
      "start_date": "2023-07-14",
      "completion_date": "2026-06-15",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-10-17T18:29:10.481Z",
      "location_count": 17,
      "location_summary": "Tucson, Arizona • Sarasota, Florida • Augusta, Georgia + 14 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Rockford",
          "state": "Illinois"
        },
        {
          "city": "Munster",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05953480"
    },
    {
      "nct_id": "NCT05468736",
      "title": "Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "6 Months to 11 Years"
      },
      "enrollment_count": 3600,
      "start_date": "2022-07-22",
      "completion_date": "2025-10-25",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-17T18:29:10.481Z",
      "location_count": 47,
      "location_summary": "Little Rock, Arkansas • Anaheim, California • Bellflower, California + 41 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Fair Oaks",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05468736"
    },
    {
      "nct_id": "NCT00119067",
      "title": "Anthrax Vaccine Clinical Trial to Assess Dose Reduction and Route Change",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Anthrax Vaccine Adsorbed",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline injection",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "61 Years",
        "sex": "ALL",
        "summary": "18 Years to 61 Years"
      },
      "enrollment_count": 1564,
      "start_date": "2002-05",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2024-05-29",
      "last_synced_at": "2026-10-17T18:29:10.481Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Silver Spring, Maryland + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Silver Spring",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00119067"
    },
    {
      "nct_id": "NCT05654441",
      "title": "Body and Social Behavior",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Psychology, Social",
        "Inflammation",
        "Defeat, Social",
        "Interaction, Social"
      ],
      "interventions": [
        {
          "name": "Influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 104,
      "start_date": "2022-10-17",
      "completion_date": "2023-12-15",
      "has_results": true,
      "last_update_posted_date": "2024-11-27",
      "last_synced_at": "2026-10-17T18:29:10.481Z",
      "location_count": 2,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05654441"
    },
    {
      "nct_id": "NCT02852005",
      "title": "Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "MVA/HIV62B vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AIDSVAX B/E vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 27,
      "start_date": "2017-01",
      "completion_date": "2019-10-29",
      "has_results": true,
      "last_update_posted_date": "2022-08-08",
      "last_synced_at": "2026-10-17T18:29:10.481Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02852005"
    },
    {
      "nct_id": "NCT00293202",
      "title": "Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "Etanercept",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kaysen, George A., M.D., Ph.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 10,
      "start_date": "2005-01",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2021-07-13",
      "last_synced_at": "2026-10-17T18:29:10.481Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00293202"
    },
    {
      "nct_id": "NCT04240535",
      "title": "Evaluation of the Safety and Efficacy of OnabotulinumtoxinA to the Depressor Anguli Oris",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Aging"
      ],
      "interventions": [
        {
          "name": "OnabotulinumtoxinA 50 UNT [Botox Cosmetic]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amir Moradi MD, MBA",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2020-01",
      "completion_date": "2020-07",
      "has_results": false,
      "last_update_posted_date": "2020-01-27",
      "last_synced_at": "2026-10-17T18:29:10.481Z",
      "location_count": 1,
      "location_summary": "Vista, California",
      "locations": [
        {
          "city": "Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04240535"
    },
    {
      "nct_id": "NCT01873885",
      "title": "Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Essential Hypertension"
      ],
      "interventions": [
        {
          "name": "Placebo Single IV (Intravenous) Infusion",
          "type": "DRUG"
        },
        {
          "name": "Experimental: Single IV Infusion Vasomera (PB1046)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2013-06",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2014-04-10",
      "last_synced_at": "2026-10-17T18:29:10.481Z",
      "location_count": 1,
      "location_summary": "Knoxville, Tennessee",
      "locations": [
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01873885"
    },
    {
      "nct_id": "NCT03135834",
      "title": "A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Meningococcal Vaccine"
      ],
      "interventions": [
        {
          "name": "MenABCWY",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rLP2086",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MenACWY-CRM",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "10 Years to 25 Years"
      },
      "enrollment_count": 1610,
      "start_date": "2017-04-24",
      "completion_date": "2022-10-25",
      "has_results": true,
      "last_update_posted_date": "2023-08-08",
      "last_synced_at": "2026-10-17T18:29:10.481Z",
      "location_count": 60,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Fountain Hills, Arizona + 45 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Fountain Hills",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Harrisburg",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03135834"
    },
    {
      "nct_id": "NCT06847698",
      "title": "Single Ascending Dose and Multiple Ascending Dose Study of AVR-48",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Safety Issues",
        "Tolerability",
        "Pharmacokinetics",
        "Pharmacodynamics"
      ],
      "interventions": [
        {
          "name": "AVR-48",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AyuVis Research, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 48,
      "start_date": "2025-06",
      "completion_date": "2025-11",
      "has_results": false,
      "last_update_posted_date": "2025-04-06",
      "last_synced_at": "2026-10-17T18:29:10.481Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06847698"
    }
  ]
}